Investor Presentaiton

Q2 2023 TRULICITY SALES DECREASED 5% Millions U.S. sales decreased 4% International sales decreased 8% Lilly U.S. TRX SOM and Market Volume 52% 1000 Market 48% 900 $1,977 $1,912 $1,936 $1,813 $1,850 $1,741 13 WK RA TRX SOM 44% 800 40% 700 36% 600 32% 500 Trulicity 28% 400 24% 300 Q1 Q2 Q3 Q4 Jun Sep Dec Mar Jun Sep Dec Mar 2021 2021 2021 2022 2022 2022 2022 2023 2023 Jun Not for promotional use 2022 12023 Source: IQVIA NPA TRX 3MMA, weekly data June 30, 2023; RA = rolling average TRX data is representative of the injectable incretin market 2023 Q2 EARNINGS 13 WK RA TRX Market Volume (000s) 29 29

View entire presentation